20 articles
Widely-used anti-aging drug combination unexpectedly increased kidney injury markers in mice, raising safety concerns for clinical use.
D+Q senolytics reshaped gut microbiota and serum metabolites to reverse diabetic osteoporosis in mice, pointing toward a novel therapeutic avenue.
Eight months of dasatinib plus quercetin treatment restored blood vessel function in aged mice by eliminating senescent endothelial cells.
4-month senolytic treatment with D+Q cleared senescent RPE cells, reduced lipofuscin, and preserved vision in a preclinical dry AMD model.
Dasatinib plus quercetin cleared senescent cells and reduced inflammation, improving alveolar bone health in aged mice.
Study shows senolytic combination therapy reduces cellular aging in gums and prevents periodontal bone loss in aging mice.
Dasatinib plus quercetin cleared senescent cells and restored kidney function in diabetic mice, offering hope for human treatment.
A landmark single-cell study maps how dasatinib + quercetin reshapes aging across multiple tissues, revealing timing matters as much as the drug itself.
Small trial tests whether dasatinib plus quercetin can improve brain blood flow and cognition in at-risk older adults.
A completed Phase 1/2 pilot trial tested whether the senolytic duo D+Q penetrates the brain in early Alzheimer's disease.
New mouse research finds the trendy D+Q senolytic combo severely damages myelin, raising red flags for longevity self-experimenters.
Dasatinib and quercetin, a leading senolytic combo, unexpectedly reduced myelination in healthy mouse brains, mimicking multiple sclerosis damage.
Clinical trial tests whether dasatinib plus quercetin can reduce liver scarring in fatty liver disease patients.
Dasatinib and quercetin clear senescent cochlear cells, reducing inflammation and preserving hair cells in aging mice.
A senolytic pairing of dasatinib and quercetin cleared senescent cells at the tendon-bone junction, dramatically improving repair strength in aged rats.
A phase 1 trial of dasatinib + quercetin in 5 early AD patients uncovers fluid biomarker changes that could guide future senolytic trials.
Dasatinib and quercetin nanoparticles improve egg quality and fertility in aging mouse ovaries by clearing senescent cells.
Isoquercitrin directly binds STAT3's SH2 domain, halting phosphorylation and dimerization to reduce diabetic kidney inflammation and fibrosis.
Alendronate-modified liposomes carrying dasatinib and quercetin doubled bone volume in chemotherapy-induced osteoporosis models.
A 2026 review evaluates how two common dietary flavonoids target senescent cells, potentially slowing aging and age-related disease.
